Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Azad

Showing results (171-180 of 199) with videos related to

Pageof 20
Sort By:
Gynecologic Oncology|January 23, 2017
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancersKim A Reiss, Joseph M Herman, Deborah Armstrong, et al.
International Journal of Surgical Oncology|July 26, 2012
Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal CancerJessica A Smith, Aaron T Wild, Aatur Singhi, et al.
Oncotarget|March 4, 2014
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancersHuili Li, Katherine B Chiappinelli, Angela A Guzzetta, et al.
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
JCI Insight|December 8, 2023
CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacyAmanda L Huff, Gabriella Longway, Jacob T Mitchell, et al.
The New England Journal of Medicine|May 6, 2026
Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic CancerBrian M Wolpin, Wungki Park, Ignacio Garrido-Laguna, et al.
The New England Journal of Medicine|June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Ebiomedicine|October 30, 2025
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation studyJacob S Thomas, Lillian L Siu, Matthew Ingham, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|January 2, 2023
Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer ClinicDaniel Li, Angela Y Jia, Jane Zorzi, et al.
Oncotarget|February 11, 2017
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer studyNilofer S Azad, Anthony El-Khoueiry, Jun Yin, et al.
Pageof 20

Showing results (171-180 of 199) with videos related to

Sort By:
Pageof 20
Gynecologic Oncology|January 23, 2017
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancersKim A Reiss, Joseph M Herman, Deborah Armstrong, et al.
International Journal of Surgical Oncology|July 26, 2012
Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal CancerJessica A Smith, Aaron T Wild, Aatur Singhi, et al.
Oncotarget|March 4, 2014
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancersHuili Li, Katherine B Chiappinelli, Angela A Guzzetta, et al.
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
JCI Insight|December 8, 2023
CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacyAmanda L Huff, Gabriella Longway, Jacob T Mitchell, et al.
The New England Journal of Medicine|May 6, 2026
Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic CancerBrian M Wolpin, Wungki Park, Ignacio Garrido-Laguna, et al.
The New England Journal of Medicine|June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Ebiomedicine|October 30, 2025
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation studyJacob S Thomas, Lillian L Siu, Matthew Ingham, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|January 2, 2023
Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer ClinicDaniel Li, Angela Y Jia, Jane Zorzi, et al.
Oncotarget|February 11, 2017
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer studyNilofer S Azad, Anthony El-Khoueiry, Jun Yin, et al.
Pageof 20